Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dawn Kaplan

Optometrist Mettawa, IL Doctor of Optometry

NPI 1922123462 CMS profile 87225

25901 N Riverwoods Rd, Mettawa, IL 60045

Open in the dashboard

General payments

$48,215

182 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dawn Kaplan of Mettawa, IL is reported in the CMS Open Payments database as having received $48,215 across 182 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,104 30
2024 General $12,244 44
2023 General $7,669 34
2022 General $2,021 15
2021 General $5,912 18
2020 General $9,849 29
2019 General $1,415 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dawn Kaplan
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Dawn Kaplan were reported at $9,104. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Dawn Kaplan Optometrist median Middle half National median
2019 $1,415 $159 $67–$371 $163
2020 $9,849 $72 $29–$165 $114
2021 $5,912 $125 $46–$292 $132
2022 $2,021 $162 $66–$374 $149
2023 $7,669 $177 $72–$406 $160
2024 $12,244 $188 $77–$427 $164
2025 $9,104 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CooperVision Inc. $27,913 73 payments
  2. Bausch & Lomb, a division of Bausch Health US, LLC $16,504 44 payments
  3. Bausch & Lomb Americas Inc. $2,207 18 payments
  4. Alcon Vision LLC $884 33 payments
  5. Johnson & Johnson Vision Care, Inc. $554 11 payments
  6. Oyster Point Pharma, Inc. $107 1 payment
  7. Harrow Eye, LLC $36 1 payment
  8. Topcon Medical Systems, Inc. $10 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13,468 10 payments
  2. Consulting Fee $9,890 9 payments
  3. Travel and Lodging $9,213 25 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $7,950 8 payments
  5. Food and Beverage $6,220 128 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $1,475 2 payments
Products named General payments · program years 2019–2025
  1. MyDay Contact Lens $18,001 43 payments
  2. INFUSE $10,388 34 payments
  3. ULTRA MULTIFOCAL TORIC $5,679 7 payments
  4. ULTRA $4,643 22 payments
  5. CVI Contact Lens $4,583 5 payments
  6. BIOTRUE ONE DAY $3,699 14 payments
  7. Clariti Contact Lens $3,155 4 payments
  8. MiSight Contact Lens $801 7 payments
  9. Acuvue $475 7 payments
  10. Precision 1 $231 11 payments
  11. Other $1,048 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$11,751

Medicare's payments for the services billed

Medicare patients

136

Average age 74

Services billed

171

77 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 58%
Arthritis 44%
Ischemic heart disease 19%
Diabetes 14%
Chronic kidney disease 13%
Cancer 13%
Osteoporosis 11%
Atrial fibrillation 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

182 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record